Ribosomal mutations as the main cause of macrolide resistance in Campylobacter jejuni and Campylobacter coli

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5939-5941

  Lehtopolku, Mirva ^a,b   Kotilainen, Pirkko ^a,b   Haanperä Heikkinen, Marjo ^a   Nakari, Ulla Maija ^a   Hänninen, Marja Liisa ^c   Huovinen, Pentti ^a,d   Siitonen, Anja ^a   Eerola, Erkki ^d   Jalava, Jari ^a   Hakanen, Antti J ^a,b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; MACROLIDE; RIBOSOMAL PROTEIN L22; RIBOSOME PROTEIN; RNA 23S; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; CAMPYLOBACTER COLI; CAMPYLOBACTER JEJUNI; CONTROLLED STUDY; GENE INSERTION; GENE MUTATION; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; RIBOSOME;

ANTI-BACTERIAL AGENTS; CAMPYLOBACTER COLI; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; DRUG RESISTANCE, BACTERIAL; ERYTHROMYCIN; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; POINT MUTATION; RIBOSOMAL PROTEINS; RNA, RIBOSOMAL, 23S; SEQUENCE ANALYSIS, DNA;

EID: 81555200529     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00314-11     Document Type: Article

References (19)

1. Allos, B. M. 2001. Campylobacter jejuni infections: update on emerging issues and trends. Clin. Infect. Dis. 32:1201-1206. (Pubitemid 32381123)
2. Bohnert, J. A., and W. V. Kern. 2005. Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrob. Agents Chemother. 49:849-852. (Pubitemid 40175716)
3. Cagliero, C., C. Mouline, A. Cloeckaert, and S. Payot. 2006. Synergy between efflux pump CmeABC and modifications in ribosomal proteins L4 and L22 in conferring macrolide resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob. Agents Chemother. 50:3893-3896. (Pubitemid 44684910)
4. Caldwell, D. B., Y. Wang, and J. Lin. 2008. Development, stability, and molecular mechanisms of macrolide resistance in Campylobacter jejuni. Antimicrob. Agents Chemother. 52:3947-3954.
5. Chittum, H. S., and W. S. Champney. 1994. Ribosomal protein gene sequence changes in erythromycin-resistant mutants of Escherichia coli. J. Bacteriol. 176:6192-6198. (Pubitemid 24313797)
6. Corcoran, D., T. Quinn, L. Cotter, and S. Fanning. 2006. An investigation of the molecular mechanisms contributing to high-level erythromycin resistance in Campylobacter. Int. J. Antimicrob. Agents 27:40-45. (Pubitemid 43042421)
7. Gibreel, A., et al. 2005. Macrolide resistance in Campylobacter jejuni and Campylobacter coli: molecular mechanism and stability of the resistance phenotype. Antimicrob. Agents Chemother. 49:2753-2759. (Pubitemid 40917588)
8. Gibreel, A., and D. E. Taylor. 2006. Macrolide resistance in Campylobacter jejuni and Campylobacter coli. J. Antimicrob. Chemother. 58:243-255. (Pubitemid 44294933)
9. Gunell, M., et al. 2010. In vitro activity of azithromycin against nontyphoidal Salmonella enterica. Antimicrob. Agents Chemother. 54:3498-3501.
10. Haanperä, M., P. Huovinen, and J. Jalava. 2005. Detection and quantification of macrolide resistance mutations at positions 2058 and 2059 of the 23S rRNA gene by pyrosequencing. Antimicrob. Agents Chemother. 49:457-460. (Pubitemid 40065833)
11. Hakanen, A., M. Lehtopolku, A. Siitonen, P. Huovinen, and P. Kotilainen. 2003. Multidrug resistance in Campylobacter jejuni strains collected from Finnish patients during 1995-2000. J. Antimicrob. Chemother. 52:1035-1039. (Pubitemid 38008431)
12. Hannula, M., and M. L. Hanninen. 2008. Effect of putative efflux pump inhibitors and inducers on the antimicrobial susceptibility of Campylobacter jejuni and Campylobacter coli. J. Med. Microbiol. 57:851-855.
13. Jones, R. N., D. J. Farrell, and I. Morrissey. 2003. Quinupristin- dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program. Antimicrob. Agents Chemother. 47:2696-2698. (Pubitemid 36919485)
14. Lehtopolku, M., et al. 2010. Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. Antimicrob. Agents Chemother. 54:1232-1236.
15. Malbruny, B., et al. 2002. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob. Agents Chemother. 46:2200-2207. (Pubitemid 34665917)
16. Nakari, U. M., A. Puhakka, and A. Siitonen. 2008. Correct identification and discrimination between Campylobacter jejuni and C. coli by a standardized hippurate test and species-specific polymerase chain reaction. Eur. J. Clin. Microbiol. Infect. Dis. 27:513-518.
17. Payot, S., et al. 2004. Relative contribution of target gene mutation and efflux to fluoroquinolone and erythromycin resistance, in French poultry and pig isolates of Campylobacter coli. Int. J. Antimicrob. Agents 23:468-472. (Pubitemid 38569595)
18. Vacher, S., A. Menard, E. Bernard, and F. Megraud. 2003. PCR-restriction fragment length polymorphism analysis for detection of point mutations associated with macrolide resistance in Campylobacter spp. Antimicrob. Agents Chemother. 47:1125-1128. (Pubitemid 36254245)
19. Zaman, S., M. Fitzpatrick, L. Lindahl, and J. Zengel. 2007. Novel mutations in ribosomal proteins L4 and L22 that confer erythromycin resistance in Escherichia coli. Mol. Microbiol. 66:1039-1050. (Pubitemid 350050427)